title: Multi-targeted approach to cancer treatment: an international translational cancer research symposium.
abstract: Whether it is chronic myeloid leukemia, ALK-expressing malignancies, or HER2-positive breast cancer, targeted-therapies for treatment of human cancers have shown great promise. However, as they hit a single molecule expressed in neoplastic cells, their use is frequently associated with development of resistance. In cancer cells many signaling pathways operate in parallel, hence the idea of multi-targeted therapy is prevailing. The Society of Translational Cancer Research held its biennial meeting in the capital city of India, Delhi from February 6th through 9th, 2014 to discuss 'Multi-targeted Approach to Treatment of Cancer'. Over 200 scientists, clinicians, trainees, and industry representatives from different countries gathered in Vigyan Bhavan, the hotspot of Delhi for four days to talk and discuss on a variety of topics related to multi-targeted therapeutic approaches. Talks were presented by leaders in the cancer research field from various countries. It became clear from this conference that coupling multiple targeted-agents or using an agent that hits an individual target in several independent locations in the disease-causing pathway(s) may be the best approach to treat different cancers.
authors.affiliation: Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, U.S.A. kmehta@mdanderson.org.
authors.forename: Kapil
authors.initials: K
authors.lastname: Mehta
authors.affiliation: Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, U.S.A.
authors.forename: Varsha
authors.initials: V
authors.lastname: Gandhi
authors.affiliation: Department of Genetics, The University of Texas MD Anderson Cancer Center, Houston, TX, U.S.A.
authors.forename: Sen
authors.initials: S
authors.lastname: Pathak
authors.affiliation: Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, U.S.A.
authors.forename: Bharat B
authors.initials: BB
authors.lastname: Aggarwal
authors.affiliation: Delhi State Cancer Institute, Dilshad Garden, Delhi, India.
authors.forename: Rajesh K
authors.initials: RK
authors.lastname: Grover
mesh_terms: D035843:Biomedical Research; D006801:Humans; D007390:International Agencies; D058990:Molecular Targeted Therapy; D009363:Neoplasm Proteins / Q000037:antagonists & inhibitors* / Q000378:metabolism; D009369:Neoplasms / Q000175:diagnosis / Q000378:metabolism / Q000517:prevention & control*; D015398:Signal Transduction; D012958:Societies, Scientific; D057170:Translational Research, Biomedical
chemical_list: D009363:Neoplasm Proteins
keywords: Prevention; multi-targeted therapy; treatment